Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on May 11, 2010, reporting on two significant financial events. The company drew down $500 million from its existing $1.25 billion credit facility to fund general corporate purposes, including common stock repurchases. This indicates a strategic use of debt for shareholder returns and operational flexibility. The filing also announced a substantial new $5.0 billion stock repurchase program, set to expire in May 2013. This new authorization follows the immediate completion of a previously announced $1.0 billion stock repurchase program, underscoring Gilead's commitment to returning capital to shareholders and its confidence in its financial position and future prospects.
Key Highlights
- 1Gilead Sciences drew $500 million under its Amended and Restated Credit Agreement on May 11, 2010.
- 2Proceeds from the $500 million loan are designated for general corporate purposes, including common stock repurchases.
- 3The company's existing credit facility has an aggregate borrowing capacity of up to $1.25 billion.
- 4Gilead's Board of Directors authorized a new stock repurchase program of up to $5.0 billion.
- 5The new $5.0 billion repurchase program is valid through May 2013.
- 6Gilead announced the completion of its previously authorized $1.0 billion stock repurchase program.
- 7The company's credit agreement matures on December 17, 2012.